Anna Jonášová

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Valeria Santini, António Almeida, Aristoteles Giagounidis et al. · Journal of Clinical Oncology · 2016 · 213 citations

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

Anna Jonášová, R Neuwírtová, Jaroslav Čermák et al. · British Journal of Haematology · 1998 · 212 citations

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 154 citations · Full text

Hematological Malignancy, Thrombosis, Interim Analysis +12

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

Uwe Platzbecker, Valeria Santini, Pierre Fenaux et al. · The Lancet · 2023 · 118 citations

Hematological Malignancy, Thrombosis, Erythropoiesis-stimulating Agents +9

Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation

Vít Pospíšil, Karin Vargová, Juraj Kokavec et al. · The EMBO Journal · 2011 · 94 citations · Full text

Epigenetic Silencing, Pu.1-directed Macrophage Differentiation, Gene Expression +8